D-dimers

Biotin-DD-XLink-mab


Biotinylated monoclonal antibody against crosslinked fibrin ("D-dimer")

Order
Quantity
Price
Status
50 µg 365 € available


Documents
Art. No. A079
Background info After proteolytic activation by thrombin, FXIIIa modifies the soft fibrin clot and thereby introducing covalent bonds. First, cross-linking between abutting γ-chains of fibrin is catalyzed and subsequently α2-antiplasmin is incorporated to further increase the resistance against fibrinolysis. Plasmin catalyses the retarded clot dissolution and the release of crosslinked fibrin degradation products (xFDPs / D-dimer). Monoclonal “D-dimer” antibodies (e.g. DD-3B6/22) are commercially available and are used in In Vitro Diagnostics (IVD) to exclude thromboembolic events. However, these monoclonals do not detect the crosslink itself but address a portion of polypeptides within the D-domain after plasmin degradation that are conformationally reactive. Zedira scientists developed a monoclonal antibody which directly recognizes the crosslinked fibrin neoepitope (DD-XLink-mab).

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Host Mouse
Isotype IgG2b κ
Immunogen Human fibrin peptides cross-linked with plasma factor XIIIa.
Specificity Specific for clot derived xFDPs (crosslinked Fibrin Degradation Products) Minor reactivity with fibrinogen degradation products (FDPs) cannot be excluded.
Appearance liquid
Formulation The antibody is stored in 10 mM sodium phosphate, 15 mM NaCl (pH 8.0), 50% glycerol
Working dilutions Optimal dilutions should be determined by the end user.
E. g. for Western-Blotting: 1 / 3,000 to 1 / 10,000 should be suitable
Storage Store at < -20 °C
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.
Related Products A076 - DD-XLink-mab

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy